S 15261

Known as: S-15261, S15261 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1994-2007
01219942007

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
AIM S 15261 is a novel oral antihyperglycaemic drug with both insulin secretagogue and insulin-sensitizing effects. The study was… (More)
Is this relevant?
2005
2005
S-15261 is a new oral anti-hyperglycemic agent that increases insulin sensitivity in various insulin-resistant animal models. The… (More)
Is this relevant?
2000
2000
S15261, a compound developed for the oral treatment of type II diabetes, is cleaved by esterases to the fragments Y415 and S15511… (More)
  • figure 1
  • table 1
  • figure 3
  • figure 2
  • figure 4
Is this relevant?
2000
2000
This meeting focused on the recent developments in the fields of adipogensis and insulin resistance. In particular, the molecular… (More)
Is this relevant?
1998
1998
The new compound S 15261 (CAS 159978-02-6) is the I-isomer of 3-[2-[2-[4-[2-(alpha-Fluorenylacetylamino)ethyl]benzoyloxy]ethylam… (More)
Is this relevant?
1997
1997
S15261 is a novel compound that has been proposed for the treatment of insulin resistance syndrome. We have studied the effects… (More)
Is this relevant?
1997
1997
A histological study has been conducted on pancreata from insulin resistant sand rats treated with S15261. As previously shown… (More)
Is this relevant?
1995
1995
Amylin has been postulated to antagonise or inhibit the action of insulin in peripheral rat tissues and thus contribute to, or be… (More)
Is this relevant?
1994
1994
A new oral agent, S15261 (the L-isomer of 3- [2- [2- [4- [2- [α-fluorenyl acetyl amino ethyl] benzoyloxy] ethyl amino] 1-methoxy… (More)
  • figure 1
  • table 2
  • table 3
  • figure 2
  • table 4
Is this relevant?